Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

Publication | Open Access

DOI Full Paper Access

133

Citations

References

2016

Year

Joel W. Neal, Suzanne E. Dahlberg, Heather A. Wakelee, Seena C. Aisner, Michaela Bowden, Ying Huang, David P. Carbone, Gregory J. Gerstner, Rachel E. Lerner, Jerome L Rubin,

The Lancet Oncology

MedicineCancer ManagementMetronomic TherapyPathologyEcog-acrin 1512Molecular OncologyCancer TreatmentPhase 2Third-line TreatmentOncologyRadiation OncologyLung CancerCancer Research